Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization

  • Aliena-Valero, Alicia
  • Hernández Jiménez, Macarena
  • López Morales, Mikahela
  • Tamayo-Torres, Eva
  • Castelló-Ruiz, Maria
  • Piñeiro, David
  • Ribo, Marc
Aptamers; Cerebroprotection; Ischemic stroke, Aptàmers; Cerebroprotecció; Ictus isquèmic, Aptámeros; Cerebroprotección; Ictus isquémico, ApTOLL, a TLR4 modulator aptamer, has demonstrated cerebroprotective effects in a permanent ischemic stroke mouse model, as well as safety and efficacy in early phase clinical trials. We carried out reverse translation research according to STAIR recommendations to further characterize the effects and mechanisms of ApTOLL after transient ischemic stroke in rats and to better inform the design of pivotal clinical trials. Adult male rats subjected to transient middle cerebral artery occlusion were treated either with ApTOLL or the vehicle intravenously at different doses and time-points. ApTOLL was compared with TAK-242 (a TLR4 inhibitor). Female rats were also studied. After neurofunctional evaluation, brains were removed for infarct/edema volume, hemorrhagic transformation, and histologic determinations. Peripheral leukocyte populations were assessed via flow cytometry. ApTOLL showed U-shaped dose-dependent cerebroprotective effects. The maximum effective dose (0.45 mg/kg) was cerebroprotective when given both before reperfusion and up to 12 h after reperfusion and reduced the hemorrhagic risk. Similar effects occurred in female rats. Both research and clinical ApTOLL batches induced slightly superior cerebroprotection when compared with TAK-242. Finally, ApTOLL modulated circulating leukocyte levels, reached the brain ischemic tissue to bind resident and infiltrated cell types, and reduced the neutrophil density. These results show the cerebroprotective effects of ApTOLL in ischemic stroke by reducing the infarct/edema volume, neurofunctional impairment, and hemorrhagic risk, as well as the peripheral and local immune response. They provide information about ApTOLL dose effects and its therapeutic time window and target population, as well as its mode of action, which should be considered in the design of pivotal clinical trials., This study was sponsored by AptaTargets S.L. (Madrid, Spain) and co-funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTC-2019-006795-1), Centro para el Desarrollo Tecnológico Industrial (IDI-20210746), and Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”) (RD16/0019/0008 and RD21/0006/0014). The funders were not involved in the study design; collection, analysis, or interpretation of data; the writing of this article; or the decision to submit it for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identifying new blood biomarkers of neuroplasticity associated with rehabilitation outcomes after stroke

  • García Rodríguez, Nicolás
  • García-Gabilondo, Miguel
  • Rodriguez, Susana
  • Tejada Ezquerro, Pedro Ignacio
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez-Mesquida, Maria Engracia
  • Valor-Blanquer, Júlia
  • Penalba Morenilla, Anna
  • Pérez, Laura Mónica
  • Inzitari, Marco
  • Lamana Vallverdú, Marcel
  • Delgado Martínez, María Pilar
  • Rosell Novel, Anna
Biomarker; Neuroplasticity; Recovery, Biomarcador; Neuroplasticitat; Recuperació, Biomarcador; Neuroplasticidad; Recuperación, Blood biomarkers in stroke patients seek to guide decision-making in clinical practice, but research on those that respond to brain recovery and their relationship with rehabilitation is still limited. Our aim was to explore the value of known neuroplasticity-related molecules, such as endostatin, growth and differentiation factor-10 (GDF-10), urokinase-type plasminogen activator (uPA) and the uPA receptor (uPAR), as blood biomarkers of recovery during poststroke rehabilitation. In an observational, prospective and multicenter study, biomarker levels were assessed after stroke in a cohort of 62 stroke patients with outcome evaluations and blood sampling before starting rehabilitation and during therapy at 1, 3 and 6 months of first visit, and in 43 control subjects. Serum levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) together with a complete battery of sensorimotor and functional tests/scales: modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA) for the upper extremity, Functional Ambulation Categories (FAC), Chedoke Arm and Hand Activity Inventory (CAHAI), 10-m walk test and the Medical Research Council (MRC). Statistical mixed linear models were built to investigate its prognostic value. The results revealed that, compared to controls, only endostatin was significantly increased at baseline after stroke (p < 0.01). Interestingly, the highest baseline GDF-10 or uPAR values were related to unfavorable scores during the complete follow-up (p < 0.05 for walking speed or MRC with GDF-10, and for FMA or MRC with uPAR), whereas decreased endostatin or increased GDF-10 biomarker changes at first month of rehabilitation were related to greater sensorimotor and functional improvements during follow-up (p < 0.05 for FMA or MRC with endostatin, and CAHAI or BI with GDF-10). Our results position endostatin, GDF-10 and uPAR as potential blood biomarkers to monitor recovery during rehabilitation after stroke., N.G-R. is doing a doctorate at the Departament de Medicina de la Universitat Autònoma de Barcelona. Research grants from the Instituto de Salud Carlos III with European Regional Development or Next Generation Founds to A.R. or J.B.S. supported this study (PI16/00981, PI19/00186, RD16/0019/0021, RD16/0019/0008, RD21/0006/0007, and RD21/0006/0014), as well as the 2021-SGR-0656 programme from the Generalitat de Catalunya-AGAUR. N.G-R. received a predoctoral fellowship from VHIR, and MG-G. received a research support grant (PERIS, SLT017/20/000197).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization

  • Aliena-Valero, Alicia
  • Hernández Jiménez, Macarena
  • López Morales, Mikahela
  • Tamayo-Torres, Eva
  • Castelló-Ruiz, Maria
  • Piñeiro, David
  • Ribo, Marc
Aptamers; Cerebroprotection; Ischemic stroke, Aptàmers; Cerebroprotecció; Ictus isquèmic, Aptámeros; Cerebroprotección; Ictus isquémico, ApTOLL, a TLR4 modulator aptamer, has demonstrated cerebroprotective effects in a permanent ischemic stroke mouse model, as well as safety and efficacy in early phase clinical trials. We carried out reverse translation research according to STAIR recommendations to further characterize the effects and mechanisms of ApTOLL after transient ischemic stroke in rats and to better inform the design of pivotal clinical trials. Adult male rats subjected to transient middle cerebral artery occlusion were treated either with ApTOLL or the vehicle intravenously at different doses and time-points. ApTOLL was compared with TAK-242 (a TLR4 inhibitor). Female rats were also studied. After neurofunctional evaluation, brains were removed for infarct/edema volume, hemorrhagic transformation, and histologic determinations. Peripheral leukocyte populations were assessed via flow cytometry. ApTOLL showed U-shaped dose-dependent cerebroprotective effects. The maximum effective dose (0.45 mg/kg) was cerebroprotective when given both before reperfusion and up to 12 h after reperfusion and reduced the hemorrhagic risk. Similar effects occurred in female rats. Both research and clinical ApTOLL batches induced slightly superior cerebroprotection when compared with TAK-242. Finally, ApTOLL modulated circulating leukocyte levels, reached the brain ischemic tissue to bind resident and infiltrated cell types, and reduced the neutrophil density. These results show the cerebroprotective effects of ApTOLL in ischemic stroke by reducing the infarct/edema volume, neurofunctional impairment, and hemorrhagic risk, as well as the peripheral and local immune response. They provide information about ApTOLL dose effects and its therapeutic time window and target population, as well as its mode of action, which should be considered in the design of pivotal clinical trials., This study was sponsored by AptaTargets S.L. (Madrid, Spain) and co-funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTC-2019-006795-1), Centro para el Desarrollo Tecnológico Industrial (IDI-20210746), and Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”) (RD16/0019/0008 and RD21/0006/0014). The funders were not involved in the study design; collection, analysis, or interpretation of data; the writing of this article; or the decision to submit it for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Identifying new blood biomarkers of neuroplasticity associated with rehabilitation outcomes after stroke

  • García Rodríguez, Nicolás
  • García-Gabilondo, Miguel
  • Rodriguez, Susana
  • Tejada Ezquerro, Pedro Ignacio
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez-Mesquida, Maria Engracia
  • Valor-Blanquer, Júlia
  • Penalba Morenilla, Anna
  • Pérez, Laura Mónica
  • Inzitari, Marco
  • Lamana Vallverdú, Marcel
  • Delgado Martínez, María Pilar
  • Rosell Novel, Anna
Biomarker; Neuroplasticity; Recovery, Biomarcador; Neuroplasticitat; Recuperació, Biomarcador; Neuroplasticidad; Recuperación, Blood biomarkers in stroke patients seek to guide decision-making in clinical practice, but research on those that respond to brain recovery and their relationship with rehabilitation is still limited. Our aim was to explore the value of known neuroplasticity-related molecules, such as endostatin, growth and differentiation factor-10 (GDF-10), urokinase-type plasminogen activator (uPA) and the uPA receptor (uPAR), as blood biomarkers of recovery during poststroke rehabilitation. In an observational, prospective and multicenter study, biomarker levels were assessed after stroke in a cohort of 62 stroke patients with outcome evaluations and blood sampling before starting rehabilitation and during therapy at 1, 3 and 6 months of first visit, and in 43 control subjects. Serum levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) together with a complete battery of sensorimotor and functional tests/scales: modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA) for the upper extremity, Functional Ambulation Categories (FAC), Chedoke Arm and Hand Activity Inventory (CAHAI), 10-m walk test and the Medical Research Council (MRC). Statistical mixed linear models were built to investigate its prognostic value. The results revealed that, compared to controls, only endostatin was significantly increased at baseline after stroke (p < 0.01). Interestingly, the highest baseline GDF-10 or uPAR values were related to unfavorable scores during the complete follow-up (p < 0.05 for walking speed or MRC with GDF-10, and for FMA or MRC with uPAR), whereas decreased endostatin or increased GDF-10 biomarker changes at first month of rehabilitation were related to greater sensorimotor and functional improvements during follow-up (p < 0.05 for FMA or MRC with endostatin, and CAHAI or BI with GDF-10). Our results position endostatin, GDF-10 and uPAR as potential blood biomarkers to monitor recovery during rehabilitation after stroke., N.G-R. is doing a doctorate at the Departament de Medicina de la Universitat Autònoma de Barcelona. Research grants from the Instituto de Salud Carlos III with European Regional Development or Next Generation Founds to A.R. or J.B.S. supported this study (PI16/00981, PI19/00186, RD16/0019/0021, RD16/0019/0008, RD21/0006/0007, and RD21/0006/0014), as well as the 2021-SGR-0656 programme from the Generalitat de Catalunya-AGAUR. N.G-R. received a predoctoral fellowship from VHIR, and MG-G. received a research support grant (PERIS, SLT017/20/000197).